**Friday, May 15**

**08:15–08:30  Welcome**

**SESSION I – Molecular pathogenesis of MPNs**  
**Chair: Robert Kralovics (Vienna)**

- **08:30-08:50**  
  Keynote lecture: Immortal hematopoietic stem cells and their epigenetic regulation  
  Peggy Goodell (Houston)

- **08:50-08:55**  
  Discussion

- **08:55-09:10**  
  Lessons about MPN pathogenesis from germline and somatic studies  
  Radek Skoda (Basel)

- **09:10-09:15**  
  Discussion

- **09:15-09:30**  
  MPN stem/cell directed therapeutics  
  Ronald Hoffman (New York)

- **09:30-09:35**  
  Discussion

- **09:35-09:50**  
  Molecular pathogenesis of PV/ET  
  Jyoti Nangalia (London)

- **09:50-09:55**  
  Discussion

- **09:55-10:05**  
  Short talk

- **10:05-10:10**  
  Discussion

- **10:10-10:30**  
  Panel discussion or controversial debates

**10:30-10:55  Coffee Break**

**SESSION II – Novel MPN therapeutics**  
**Chair: Radek Skoda (Basel)**

- **10:55-11:10**  
  Targeting the MAPK pathway  
  Sara Meyer (Basel)

- **11:10-11:15**  
  Discussion

- **11:15-11:30**  
  Role of the JH2 pseudokinase in MPN biology and therapy  
  Olli Silvennoinen (Helsinki)

- **11:30-11:35**  
  Discussion

- **11:35-11:50**  
  Structure based insights into MPN therapeutics  
  Stefan N. Constantinescu (Brussels)

- **11:50-11:55**  
  Discussion

- **11:55-12:10**  
  Novel approaches to targeting CALR-mutant MPN  
  Robert Kralovics (Vienna)

- **12:10-12:15**  
  Discussion

- **12:15-12:25**  
  Short talk

- **12:25-12:30**  
  Discussion
12:30-12:50  Panel discussion or controversial debates

12:50-14:35  Lunch

13:20-14:20  Satellite symposium (slot already booked)

SESSION III – MPN Initiation and clonal evolution
Chair: TBA

14:35-14:50  Single cell approaches to deciphering MPN biology
Stephen Oh (St Louis)

14:50-14:55  Discussion

14:55-15:10  Single cell studies to uncover novel insights into MPN pathogenesis
Adam Mead (Oxford)

15:10-15:15  Discussion

15:15-15:30  Role of inflammation in MPN initiation and progression
Angela Fleischman (Irvine)

15:30-15:35  Discussion

15:35-15:50  Non-genetic mechanisms of clonal expansion
David Kent (York)

15:50-15:55  Discussion

15:55-16:05  Short talk

16:05-16:10  Discussion

16:10-16:30  Panel discussion or controversial debates

16:30-17:00  Coffee break

SESSION IV – Murine MPN models and pathogenesis/therapeutic studies
Chair: Ann Mullally (Boston)

17:00-17:15  Targeting the microenvironment as a therapeutic approach in MPN
Simón Méndez-Ferrer (Cambridge)

17:15-17:20  Discussion

17:20-17:35  LSD1 inhibition as a therapeutic approach in MPN
Heike L. Pahl (Freiburg)

17:35-17:40  Discussion

17:40-17:55  NGS analysis and evaluation of clonal evolution during treatment in MPN in clinical practice
Bruno Cassinat (Paris)

17:55-18:00  Discussion

18:00-18:15  Pathogenesis and therapy of MPN-associated thrombosis
Chloé James (Bordeaux)

18:15-18:20  Discussion

18:20-18:35  Modeling progression to myelofibrosis
Jean-Luc Villeval (Paris)

18:35-18:40  Discussion

18:40-18:50  Short talk

18:50-18:55  Discussion

18:55-19:15  Panel discussion or controversial debates
19:15  Get together and poster walks (stand up cocktails and buffet dinner for all)

**Saturday, May 16**

**09:00-10:00**  Satellite symposium (slot already booked)

**09:00-10:00**  3 Simultaneous Meet the Expert sessions (non-clinical):
1. Role of inflammation in MPN  
   Angela Fleischman (Irvine)
2. Cellular and molecular regulators of HSCs in myeloid malignancies  
   David Kent (York)
3. HSC niches in MPN  
   Simón Méndez-Ferrer (Cambridge)

**SESSION V – Molecular pathogenesis and therapy of MPN progression and leukaemic transformation**  
Chair: Raajit K. Rampal (New York)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10-10:25</td>
<td>Unusual firms of eosinophilias (FGFR1 inhibitors, MoAb for other eosinophilias)</td>
<td>Andreas Reiter (Mannheim)</td>
</tr>
<tr>
<td>10:25-10:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:30-10:45</td>
<td>Genetic studies of MPN leukaemic transformation</td>
<td>Vikas Gupta (Toronto)</td>
</tr>
<tr>
<td>10:45-10:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**10:50-11:20**  Coffee break

**11:20-11:35**  Therapeutic approaches in post-MPN AML  
John O. Mascarenhas (New York)

**11:35-11:40**  Discussion

**11:40-11:55**  Transplantation as a therapeutic in post-MPN AML  
Nicolaus Kröger (Hamburg)

**11:55-12:00**  Discussion

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-12:10</td>
<td>Short talk</td>
<td></td>
</tr>
<tr>
<td>12:10-12:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:15-12:25</td>
<td>Short talk</td>
<td></td>
</tr>
<tr>
<td>12:25-12:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:30-12:50</td>
<td>Panel discussion or controversial debates</td>
<td></td>
</tr>
</tbody>
</table>

**12:50-14:30**  Lunch

**13:20-14:20**  Satellite symposium (slot already booked)

**SESSION VI – Recent advances in therapeutics (1)**  
Chair: Jean-Jacques Kiladjian (Paris)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-14:50</td>
<td>Keynote lecture: Combination therapies for myelofibrosis</td>
<td>Ruben Mesa (San Antonio)</td>
</tr>
<tr>
<td>14:50-14:55</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:55-15:10</td>
<td>Prognostic scores in MPN</td>
<td>Alessandro M. Vannucchi (Florence)</td>
</tr>
<tr>
<td>15:10-15:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:30-15:35</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
15:35-15:50 Molecular pathogenesis of progression from MPN to AML  Raajit K. Rampal (New York)
15:50-15:55 Discussion
15:55-16:15 Panel discussion or short communications or controversial debates

16:15-16:45 Coffee break

SESSION VII – Recent advances in therapeutics (2)
Chair: Alessandro M. Vannucchi (Florence)
16:45-17:00 Insights in diagnosis and management of CMML  Eric Solary (Paris)
17:00-17:05 Discussion
17:05-17:20 ET Therapy  Tiziano Barbui (Bergamo)
17:20-17:25 Discussion
17:25-17:40 Therapy of overlap MPN/MDS syndromes  Lionel Ades (Paris)
17:40-17:45 Discussion
17:45-18:00 Role of aspirin in ET  Stéphane Giraudier (Paris)
18:00-18:05 Discussion
18:05-18:25 Panel discussion or controversial debates

Free evening

Sunday, May 17

07:30-8:30 3 Simultaneous Breakfast Meet the Expert Sessions (Clinical):
1. Title TBA  Raajit K. Rampal (New York)
2. How to recognize and manage ruxolitinib treatment failure?  John O. Mascarenhas (New York)
3. MPN diagnosis: The place of Red cell Mass measurement in the molecular Era  Stéphane Giraudier (Paris)

SESSION VIII – Molecular pathogenesis of MPNs
Chair: Angela Fleischman (Irvine)
08:40-08:55 CALR mutations in the development of MPN using mouse modeling  Caroline Marty (Villejuif)
08:55-09:00 Discussion
09:00-09:15 Initiation and progression of CALR mutant MPN  Ann Mullally (Boston)
09:15-09:20 Discussion
09:20-09:35 Deciphering the role of clonal evolution in MPN pathogenesis and progression  Andrew Dunbar (New York)
09:35-09:40 Discussion
09:40-09:50 Short talk
09:50-09:55 Discussion
09:55-10:05 Short talk
10:05-10:10 Discussion
10:10-10:30 Panel discussion or controversial debates
**10:30-11:00**  
*Coffee break*

**SESSION IX – Novel MPN therapeutics**  
*Chair: Stefan N. Constantinescu (Brussels)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:15</td>
<td>Targeting splicing factors</td>
<td>Timothy Graubert (Boston)</td>
</tr>
<tr>
<td>11:15-11:20</td>
<td><em>Discussion</em></td>
<td></td>
</tr>
<tr>
<td>11:20-11:35</td>
<td>Targeting aberrant self-renewal in MPN</td>
<td>Catriona Jamieson (La Jolla)</td>
</tr>
<tr>
<td>11:35-11:40</td>
<td><em>Discussion</em></td>
<td></td>
</tr>
<tr>
<td>11:40-11:55</td>
<td>Novel approaches to mastocytosis therapy</td>
<td>Jason Gotlib (Stanford)</td>
</tr>
<tr>
<td>11:55 -12:00</td>
<td><em>Discussion</em></td>
<td></td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>Novel JAK inhibitors for myelofibrosis</td>
<td>Prithviraj Bose (Houston)</td>
</tr>
<tr>
<td>12:15-12:20</td>
<td><em>Discussion</em></td>
<td></td>
</tr>
<tr>
<td>12:20-12:40</td>
<td><em>Panel discussion or controversial debates</em></td>
<td></td>
</tr>
</tbody>
</table>

**12:40-12:55**  
*Closing Remarks*

**MEETING CLOSURE**

*pending confirmation*